Heart & circulation

• Blood pressure: Studies have linked tirzepatide with small drops in systolic/diastolic BP. Weight loss likely explains some of this
• Cholesterol & triglycerides: People taking tirzepatide often see friendlier lipid numbers (↓ triglycerides/LDL/total cholesterol, ↑ HDL).
• Big-picture outcomes: A large cardiovascular outcomes trial is running to confrm whether it lowers risks like heart attack and stroke. Results look promising.

Liver health (NAFLD/NASH)

• What researchers are seeing: Lower liver fat and improved liver enzymes (ALT/AST) alongside weight loss.
• Still to prove: Efects on liver scarring (fbrosis) are being studied..
• Takeaway: Not a licensed liver treatment; if you have NAFLD/NASH, combine weight loss eforts with GP/hepatology advice and monitoring.

PCOS (polycystic ovary syndrome)

• Why it might help: Weight loss and better insulin sensitivity can improve cycle regularity and reduce symptoms linked to high androgens.

Kidneys (chronic kidney disease)

• The signal: Across GLP-1-type medicines, there are hints of kidney protection in diabetes (e.g., lower albumin in urine, slower eGFR decline). Tirzepatide shows similar trends in early analysis.
• The catch: Dehydration from tummy side-efects can trigger acute kidney issues—stay hydrated and follow sick-day rules.
• Bottom line: Not a kidney medicine; consider it only for weight management where appropriate, with renal checks as advised.

Obstructive sleep apnoea (OSA)

• Weight matters: Losing weight generally improves OSA severity and symptoms.
• Licensing varies: Tirzepatide is authorised for OSA in the USA; UK licensing hasn’t changed at the time of writing.
• Reality check: Keep using CPAP or dental devices as prescribed—think of potential tirzepatide efects as extra help from weight loss.

Prediabetes & metabolic syndrome

• What’s promising: Better insulin sensitivity, improved BP/lipids and weight loss together may delay or prevent type 2 diabetes.

Infammation (CRP and friends)

• Early observations: Some studies report lower CRP, a marker of infammation, alongside weight loss.
• So what?: Useful to watch, but we don’t yet know how much this changes long-term risks on its own.

Safety snapshot (always read the PIL and speak to a clinician)

• Do not use if you’re pregnant, trying for pregnancy, or breastfeeding
• Tell your clinician about all medicines and conditions (especially pancreas, gallbladder, eye, kidney, thyroid or heart rhythm issues).
• Common side-efects: nausea, vomiting, diarrhoea, constipation, indigestion— often during dose increases and usually settle.
• Seek urgent advice for severe tummy pain (possible pancreatitis), dehydration, allergic reaction, vision changes, or any worrying symptom.

The takeaway

Tirzepatide’s main job is weight management (plus type 2 diabetes in other indications). As weight drops and metabolism improves, you may see knock-on benefts for blood pressure, cholesterol, fatty liver, sleep apnoea and more—a lot of research taking place-watch this space

Thinking about whether Mounjaro is right for you? Book a Mederoo consultation to discuss your health history, goals and the safest plan forward.